If Phase III trials are successful, Novo Nordisk may seek FDA and EMA approval in the next few years
Although research is ongoing, early evidence suggests that KPV can: Reduce inflammation within the GI tract
Enhanced Protocol (FDA/Clinical) Note: The standard protocol above uses research peptide community doses
PubMed Sosne G, Qiu P, Goldstein AL, Wheater M
Despite headlines suggesting the FDA approved BPC-157, it did not
However, these spikes operate on shorter timescales than the calcium transients and the longer temporal decay of intracellular calcium (on the order of tens of seconds, Fig 3) may be crucial for the negative feedback of the GPCR pathway